Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models have?
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models has 235 citations in the OpenAlex counts ScholarIQ stores.
When was Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models published?
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models has 2018 year in the ScholarIQ index.
What is the open-access status of Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models?
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models has bronze oa status in the ScholarIQ index.
What is the DOI of Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models?
The DOI for Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models is on the source record.
What is the PMID of Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models?
The PMID for Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models is on the source record.
What is the OpenAlex record for Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models?
The OpenAlex for Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models is on the source record.